Ron A A MathÃ't

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1629441/publications.pdf

Version: 2024-02-01

196 papers 6,075 citations

76326 40 h-index 70 g-index

196 all docs

196 docs citations

196 times ranked 7275 citing authors

#	Article	IF	CITATIONS
1	Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients With Crohn Disease: Posthoc Analysis of the LOVE-CD Study. Inflammatory Bowel Diseases, 2022, 28, 689-699.	1.9	9
2	Saliva as a sampling matrix for therapeutic drug monitoring of gentamicin in neonates: A prospective population pharmacokinetic and simulation study. British Journal of Clinical Pharmacology, 2022, 88, 1845-1855.	2.4	9
3	Combining factor VIII levels and thrombin/plasmin generation: A population pharmacokineticâ€pharmacodynamic model for patients with haemophilia A. British Journal of Clinical Pharmacology, 2022, 88, 2757-2768.	2.4	6
4	Development and Validation of a Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Assay for the Determination of Total and Unbound Ciprofloxacin Concentrations in Human Plasma. Therapeutic Drug Monitoring, 2022, Publish Ahead of Print, .	2.0	2
5	Design of a Prospective Study on Pharmacokinetic-Guided Dosing of Prophylactic Factor Replacement in Hemophilia A and B (OPTI-CLOT TARGET Study). TH Open, 2022, 06, e60-e69.	1.4	1
6	Serum drug levels and anti-drug antibodies in the context of dose tapering by interval prolongation of adalimumab, etanercept and ustekinumab in psoriasis patients: results of the CONDOR trial. Journal of Dermatological Treatment, 2022, 33, 2680-2684.	2.2	4
7	Is pharmacokinetic-guided dosing of desmopressin and von Willebrand factor-containing concentrates in individuals with von Willebrand disease or low von Willebrand factor reliable and feasible? A protocol for a multicentre, non-randomised, open label cohort trial, the OPTI-CLOT: to WiN study. BMI Open, 2022, 12, e049493.	1.9	2
8	Population pharmacokinetics of intravenous cefotaxime indicates that higher doses are required for critically ill children. Journal of Antimicrobial Chemotherapy, 2022, 77, 1725-1732.	3.0	1
9	Editorial: subcutaneous CTâ€P13 in Crohn's disease and ulcerative colitis–small change, big consequences. Authors' reply. Alimentary Pharmacology and Therapeutics, 2022, 55, 253-254.	3.7	O
10	Does difference between label and actual potency of factor VIII concentrate affect pharmacokineticâ€guided dosing of replacement therapy in haemophilia A?. Haemophilia, 2022, , .	2.1	2
11	Quantification of the relationship between desmopressin concentration and Von Willebrand factor in Von Willebrand disease type 1: A pharmacodynamic study. Haemophilia, 2022, 28, 814-821.	2.1	1
12	Deep compartment models: A deep learning approach for the reliable prediction of timeâ€series data in pharmacokinetic modeling. CPT: Pharmacometrics and Systems Pharmacology, 2022, 11, 934-945.	2.5	8
13	SYMPHONY consortium: Orchestrating personalized treatment for patients with bleeding disorders. Journal of Thrombosis and Haemostasis, 2022, 20, 2001-2011.	3.8	6
14	A phase lb/II study of regorafenib and paclitaxel in patients with beyond first-line advanced esophagogastric carcinoma (REPEAT). Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211091.	3.2	3
15	Application of <scp>SHAP</scp> values for inferring the optimal functional form of covariates in pharmacokinetic modeling. CPT: Pharmacometrics and Systems Pharmacology, 2022, 11, 1100-1110.	2.5	8
16	Clinical Pharmacokinetics of Gentamicin in Various Patient Populations and Consequences for Optimal Dosing for Gram-Negative Infections: An Updated Review. Clinical Pharmacokinetics, 2022, 61, 1075-1094.	3.5	16
17	The association between desmopressin exposure, FVIII response and side effects. Haemophilia, 2021, 27, e506-e509.	2.1	O
18	Individualized dosing guidelines for PEGasparaginase and factors influencing the clearance: a population pharmacokinetic model. Haematologica, 2021, 106, 1254-1261.	3.5	11

#	Article	IF	CITATIONS
19	Modelling of the relationship between infliximab exposure, faecal calprotectin and endoscopic remission in patients with Crohn's disease. British Journal of Clinical Pharmacology, 2021, 87, 106-118.	2.4	18
20	Why we should sample sparsely and aim for a higher target: Lessons from modelâ€based therapeutic drug monitoring of vancomycin in intensive care patients. British Journal of Clinical Pharmacology, 2021, 87, 1234-1242.	2.4	4
21	Dosing of factor VIII concentrate by ideal body weight is more accurate in overweight and obese haemophilia A patients. British Journal of Clinical Pharmacology, 2021, 87, 2602-2613.	2.4	6
22	Does dose reduction of renally cleared antibiotics in patients with impaired renal function lead to adequate drug exposure? A systematic review. Clinical Microbiology and Infection, 2021, 27, 352-363.	6.0	10
23	Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial. Scandinavian Journal of Gastroenterology, 2021, 56, 145-154.	1.5	61
24	Population Pharmacokinetics of Clotting Factor Concentrates and Desmopressin in Hemophilia. Clinical Pharmacokinetics, 2021, 60, 1-16.	3.5	3
25	Transcapillary escape rate of 1251-albumin in relation to timing of blood sampling: the need for standardization. EJNMMI Radiopharmacy and Chemistry, 2021, 6, 9.	3.9	0
26	Wound infection following implant removal of foot, ankle, lower leg or patella; aÂprotocol for a multicenter randomized controlled trial investigating the (cost-)effectiveness of 2Âg of prophylactic cefazolin compared to placebo (WIFI-2 trial). BMC Surgery, 2021, 21, 69.	1.3	1
27	A Phase II Study Demonstrates No Feasibility of Adjuvant Treatment with Six Cycles of S-1 and Oxaliplatin in Resectable Esophageal Adenocarcinoma, with ERCC1 as Biomarker for Response to SOX. Cancers, 2021, 13, 839.	3.7	2
28	In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates. European Journal of Clinical Pharmacology, 2021, 77, 1193-1200.	1.9	3
29	Population pharmacokinetics of the von Willebrand factor–factor VIII interaction in patients with von Willebrand disease. Blood Advances, 2021, 5, 1513-1522.	5.2	5
30	Development and Validation of a Highly Sensitive Liquid Chromatography-Tandem Mass Spectrometry Technique to Determine Levamisole in Plasma and Saliva. Therapeutic Drug Monitoring, 2021, 43, 279-285.	2.0	1
31	Population Pharmacokinetics and Probability of Target Attainment of Different Dosing Regimens of Ceftazidime in Critically Ill Patients with a Proven or Suspected Pseudomonas aeruginosa Infection. Antibiotics, 2021, 10, 612.	3.7	9
32	Validation of a perioperative population factor VIII pharmacokinetic model with a large cohort of pediatric hemophilia a patients. British Journal of Clinical Pharmacology, 2021, 87, 4408-4420.	2.4	4
33	Current Ceftriaxone Dose Recommendations are Adequate for Most Critically Ill Children: Results of a Population Pharmacokinetic Modeling and Simulation Study. Clinical Pharmacokinetics, 2021, 60, 1361-1372.	3.5	9
34	A Phase Ib Clinical Trial of Metformin and Chloroquine in Patients with IDH1-Mutated Solid Tumors. Cancers, 2021, 13, 2474.	3.7	13
35	Evaluation of the pharmacokinetics of prednisolone in paediatric patients with acute lymphoblastic leukaemia treated according to Dutch Childhood Oncology Group protocols and its relation to treatment response. British Journal of Haematology, 2021, 194, 423-432.	2.5	3
36	Perioperative pharmacokinetic-guided factor VIII concentrate dosing in haemophilia (OPTI-CLOT trial): an open-label, multicentre, randomised, controlled trial. Lancet Haematology,the, 2021, 8, e492-e502.	4.6	9

#	Article	IF	CITATIONS
37	Population pharmacokinetics of infliximab in children with juvenile idiopathic arthritis. Therapeutic Drug Monitoring, 2021, Publish Ahead of Print, .	2.0	1
38	Pharmacokinetics of perioperative FVIII in adult patients with haemophilia A: An external validation and development of an alternative population pharmacokinetic model. Haemophilia, 2021, 27, 974-983.	2.1	3
39	Population pharmacokinetic modeling of factor concentrates in hemophilia: an overview and evaluation of best practice. Blood Advances, 2021, 5, 4314-4325.	5.2	3
40	Population pharmacokinetics of subcutaneous infliximab CTâ€P13 in Crohn's disease and ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2021, 54, 1309-1319.	3.7	24
41	Comparison of the Pharmacokinetic Properties of Extended Half-Life and Recombinant Factor VIII Concentrates by In Silico Simulations. Thrombosis and Haemostasis, 2021, 121, 731-740.	3.4	5
42	Sedation With Midazolam After Cardiac Surgery in Children With and Without Down Syndrome: A Pharmacokinetic-Pharmacodynamic Study. Pediatric Critical Care Medicine, 2021, 22, e259-e269.	0.5	1
43	Rapid stromal remodeling by shortâ€ŧerm VEGFR2 inhibition increases chemotherapy delivery in esophagogastric adenocarcinoma. Molecular Oncology, 2020, 14, 704-720.	4.6	7
44	One piece of the puzzle: Population pharmacokinetics of FVIII during perioperative Haemate $P\hat{A}^{@}/Humate$ $P\hat{A}^{@}$ treatment in von Willebrand disease patients. Journal of Thrombosis and Haemostasis, 2020, 18, 295-305.	3.8	6
45	Sorafenib for Patients with Hepatocellular Carcinoma and Child-Pugh B Liver Cirrhosis: Lessons Learned from a Terminated Study. Oncologist, 2020, 25, e1274-e1279.	3.7	11
46	Efficacy and safety of FOLFIRINOX as salvage treatment in advanced biliary tract cancer: an open-label, single arm, phase 2 trial. British Journal of Cancer, 2020, 122, 634-639.	6.4	40
47	Pharmacokinetics and population pharmacokinetics in pediatric oncology. Pediatric Blood and Cancer, 2020, 67, e28132.	1.5	7
48	Population Pharmacokinetics of Ganciclovir in Critically III Patients. Therapeutic Drug Monitoring, 2020, 42, 295-301.	2.0	8
49	The effects of fasting on drug metabolism. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 79-85.	3.3	20
50	Monitoring of Adalimumab Concentrations at Home in Patients with Inflammatory Bowel Disease Using Dried Blood Samples. Therapeutic Drug Monitoring, 2020, 42, 289-294.	2.0	13
51	Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2–Positive Esophageal Adenocarcinoma: TRAP Study. Journal of Clinical Oncology, 2020, 38, 462-471.	1.6	44
52	Pharmacokinetic/pharmacodynamic target attainment of ciprofloxacin in adult patients on general wards with adequate and impaired renal function. International Journal of Antimicrobial Agents, 2020, 56, 106166.	2.5	10
53	Population Pharmacokinetic Modeling of von Willebrand Factor Activity in von Willebrand Disease Patients after Desmopressin Administration. Thrombosis and Haemostasis, 2020, 120, 1407-1416.	3.4	3
54	Development and validation of an LC-MS/MS method for simultaneous quantification of co-administered trastuzumab and pertuzumab. MAbs, 2020, 12, 1795492.	5.2	11

#	Article	IF	CITATIONS
55	A Novel, Enriched Population Pharmacokinetic Model for Recombinant Factor VIII-Fc Fusion Protein Concentrate in Hemophilia A Patients. Thrombosis and Haemostasis, 2020, 120, 747-757.	3.4	8
56	Optimizing Predictive Performance of Bayesian Forecasting for Vancomycin Concentration in Intensive Care Patients. Pharmaceutical Research, 2020, 37, 171.	3.5	8
57	Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: Combining thrombin and plasmin generation. Journal of Thrombosis and Haemostasis, 2020, 18, 3222-3231.	3.8	16
58	The value of sorafenib trough levels in patients with advanced hepatocellular carcinoma – a substudy of the SORAMIC trial. Acta Oncológica, 2020, 59, 1028-1035.	1.8	11
59	von Willebrand Factor and Factor VIII Clearance in Perioperative Hemophilia A Patients. Thrombosis and Haemostasis, 2020, 120, 1056-1065.	3.4	5
60	Prediction of Drug Exposure in Critically Ill Encephalopathic Neonates Treated With Therapeutic Hypothermia Based on a Pooled Population Pharmacokinetic Analysis of Seven Drugs and Five Metabolites. Clinical Pharmacology and Therapeutics, 2020, 108, 1098-1106.	4.7	12
61	Optimising the dose of clonidine to achieve sedation in intensive care unit patients with population pharmacokinetics. British Journal of Clinical Pharmacology, 2020, 86, 1620-1631.	2.4	9
62	A Novel Quantitative Method for Analyzing Desmopressin in Human Plasma Using Liquid Chromatography–Tandem Mass Spectrometry. Therapeutic Drug Monitoring, 2020, 42, 880-885.	2.0	1
63	Combining Brain Microdialysis and Translational Pharmacokinetic Modeling to Predict Drug Concentrations in Pediatric Severe Traumatic Brain Injury: The Next Step Toward Evidence-Based Pharmacotherapy?. Journal of Neurotrauma, 2019, 36, 111-117.	3.4	15
64	Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis. Clinical Pharmacokinetics, 2019, 58, 15-37.	3.5	91
65	Differential effects of a 40-hour fast and bile acid supplementation on human GLP-1 and FGF19 responses. American Journal of Physiology - Endocrinology and Metabolism, 2019, 317, E494-E502.	3.5	9
66	832 – Dashboard Driven Dosing of Infliximab is Superior to Conventional Treatment in Inflammatory Bowel Disease: the Precision Randomized Controlled Trial. Gastroenterology, 2019, 156, S-180-S-181.	1.3	3
67	Current dosing practices for perioperative factor VIII concentrate treatment in mild haemophilia A patients result in FVIII levels above target. Haemophilia, 2019, 25, 960-968.	2.1	4
68	Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn's Disease. Gastroenterology, 2019, 157, 997-1006.e6.	1.3	86
69	Tumor necrosis factor-mediated disposition of infliximab in ulcerative colitis patients. Journal of Pharmacokinetics and Pharmacodynamics, 2019, 46, 543-551.	1.8	8
70	Pharmacokinetics of golimumab in moderate to severe ulcerative colitis: the GO-KINETIC study. Scandinavian Journal of Gastroenterology, 2019, 54, 700-706.	1.5	16
71	Desmopressin treatment combined with clotting factor VIII concentrates in patients with non-severe haemophilia A: protocol for a multicentre single-armed trial, the DAVID study. BMJ Open, 2019, 9, e022719.	1.9	7
72	External Evaluation of Population Pharmacokinetic Models of Vancomycin in Large Cohorts of Intensive Care Unit Patients. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	40

#	Article	IF	Citations
73	Pharmacokinetic-guided dosing of factor VIII concentrate in a morbidly obese severe haemophilia A patient undergoing orthopaedic surgery. BMJ Case Reports, 2019, 12, bcr-2018-226812.	0.5	2
74	Dried blood samples can support monitoring of infliximab concentrations in patients with inflammatory bowel disease: A clinical validation. British Journal of Clinical Pharmacology, 2019, 85, 1544-1551.	2.4	26
75	Population Pharmacokinetics with Monte Carlo Simulations of Gentamicin in a Population of Severely Ill Adult Patients from Sub-Saharan Africa. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	7
76	Target site antibiotic concentrations in orthopedic/trauma extremity surgery: is prophylactic cefazolin adequately dosed? A systematic review and meta-analysis. Monthly Notices of the Royal Astronomical Society: Letters, 2019, 90, 97-104.	3.3	12
77	Prevention of relapses with levamisole as adjuvant therapy in children with a first episode of idiopathic nephrotic syndrome: study protocol for a double blind, randomised placebo-controlled trial (the LEARNS study). BMJ Open, 2019, 9, e027011.	1.9	16
78	Pharmacokinetics of prednisolone in children: an open-label, randomised, two-treatment cross-over trial investigating the bioequivalence of different prednisolone formulations in children with airway disease. BMJ Paediatrics Open, 2019, 3, e000520.	1.4	4
79	Strategies for Individualized Dosing of Clotting Factor Concentrates and Desmopressin in Hemophilia A and B. Therapeutic Drug Monitoring, 2019, 41, 192-212.	2.0	10
80	Efficacy and safety of FOLFIRINOX in advanced biliary tract cancer after failure of gemcitabine plus cisplatin: A phase II trial Journal of Clinical Oncology, 2019, 37, 4086-4086.	1.6	9
81	Pharmacokinetics and pharmacodynamic target attainment of ceftriaxone in adult severely ill sub-Saharan African patients: a population pharmacokinetic modelling study. Journal of Antimicrobial Chemotherapy, 2018, 73, 1620-1629.	3.0	26
82	CNS penetration of ART in HIV-infected children. Journal of Antimicrobial Chemotherapy, 2018, 73, 484-489.	3.0	21
83	Pharmacokinetics and Pharmacodynamic Target Attainment of Benzylpenicillin in an Adult Severely Ill Sub-Saharan African Patient Population. Clinical Infectious Diseases, 2018, 66, 1261-1269.	5.8	3
84	An effective modestly intensive reâ€induction regimen with bortezomib in relapsed or refractory paediatric acute lymphoblastic leukaemia. British Journal of Haematology, 2018, 181, 523-527.	2.5	12
85	Evaluation of a System-Specific Function To Describe the Pharmacokinetics of Benzylpenicillin in Term Neonates Undergoing Moderate Hypothermia. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	8
86	Explaining Interpatient Variability in Adalimumab Pharmacokinetics in Patients With Crohn's Disease. Therapeutic Drug Monitoring, 2018, 40, 202-211.	2.0	26
87	A phase Ib study of everolimus combined with metformin for patients with advanced cancer. Investigational New Drugs, 2018, 36, 53-61.	2.6	15
88	Population pharmacodynamic modelling of midazolam induced sedation in terminally ill adult patients. British Journal of Clinical Pharmacology, 2018, 84, 320-330.	2.4	16
89	Short-Term Fasting Alters Pharmacokinetics of Cytochrome P450 Probe Drugs: Does Protein Binding Play a Role?. European Journal of Drug Metabolism and Pharmacokinetics, 2018, 43, 251-257.	1.6	8
90	Positioning extended halfâ€life concentrates for future use: a practical proposal. Haemophilia, 2018, 24, e369-e372.	2.1	4

#	Article	IF	CITATIONS
91	Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 535-548.	2.3	50
92	Pharmacokinetic Modelling to Predict FVIII:C Response to Desmopressin and Its Reproducibility in Nonsevere Haemophilia A Patients. Thrombosis and Haemostasis, 2018, 47, 621-629.	3.4	8
93	Nutritional Status Differentially Alters Cytochrome P450 3A4 (CYP3A4) and Uridine $5\hat{a}\in^2$ -Diphospho-Glucuronosyltransferase (UGT) Mediated Drug Metabolism: Effect of Short-Term Fasting and High Fat Diet on Midazolam Metabolism. European Journal of Drug Metabolism and Pharmacokinetics. 2018, 43, 751-767.	1.6	7
94	Feasibility study of trastuzumab (T) and pertuzumab (P) added to neoadjuvant chemoradiotherapy (nCRT) in resectable HER2+ esophageal adenocarcinoma (EAC) patients (pts): The TRAP study Journal of Clinical Oncology, 2018, 36, 4057-4057.	1.6	4
95	Population pharmacokinetics of intravenous clonidine for sedation during paediatric extracorporeal membrane oxygenation and continuous venovenous hemofiltration. British Journal of Clinical Pharmacology, 2017, 83, 1227-1239.	2.4	24
96	Effect of Short-Term Fasting on Systemic Cytochrome P450-Mediated Drug Metabolism in Healthy Subjects: A Randomized, Controlled, Crossover Study Using a Cocktail Approach. Clinical Pharmacokinetics, 2017, 56, 1231-1244.	3.5	18
97	Hypoalbuminaemia and decreased midazolam clearance in terminally ill adult patients, an inflammatory effect?. British Journal of Clinical Pharmacology, 2017, 83, 1701-1712.	2.4	23
98	Population pharmacokinetics of intravenous Erwinia asparaginase in pediatric acute lymphoblastic leukemia patients. Haematologica, 2017, 102, 552-561.	3.5	14
99	Golimumab for moderate to severe ulcerative colitis. Expert Review of Gastroenterology and Hepatology, 2017, 11, 401-406.	3.0	7
100	Quantitative Method for Simultaneous Analysis of Acetaminophen and 6 Metabolites. Therapeutic Drug Monitoring, 2017, 39, 172-179.	2.0	5
101	Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with <i>IDH1 < /i>i>mutated or <i>IDH2 < /i>i>mutated solid tumours. BMJ Open, 2017, 7, e014961.</i></i>	1.9	69
102	Determinants of gentamicin concentrations in critically ill patients: a population pharmacokinetic analysis. International Journal of Antimicrobial Agents, 2017, 49, 204-211.	2.5	30
103	Population Pharmacokinetics and Dosing Considerations for Gentamicin in Newborns with Suspected or Proven Sepsis Caused by Gram-Negative Bacteria. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	16
104	Pharmacokinetics of Sâ€ketamine during prolonged sedation at the pediatric intensive care unit. Paediatric Anaesthesia, 2017, 27, 1098-1107.	1.1	12
105	Systemic effects of angiogenesis inhibition alter pharmacokinetics and intratumoral delivery of <i>nab</i> -paclitaxel. Drug Delivery, 2017, 24, 1801-1810.	5.7	5
106	Pharmacokinetics of dabigatran etexilate and rivaroxaban in patients with short bowel syndrome requiring parenteral nutrition: The PDER PAN study. Thrombosis Research, 2017, 160, 76-82.	1.7	13
107	Therapeutic Drug Monitoring of Gentamicin Peak Concentrations in Critically III Patients. Therapeutic Drug Monitoring, 2017, 39, 522-530.	2.0	20
108	Paracetamol clinical dosing routine leads to paracetamol underexposure in an adult severely ill sub-Saharan African hospital population: a drug concentration measurement study. BMC Research Notes, 2017, 10, 671.	1.4	4

7

#	Article	IF	Citations
109	Survival analysis of a phase IB/II study of everolimus and metformin for patients with advanced cancer Journal of Clinical Oncology, 2017, 35, e14020-e14020.	1.6	0
110	Pharmacokinetic-guided dosing of factor VIII concentrate in a patient with haemophilia during renal transplantation. BMJ Case Reports, 2016, 2016, bcr2016217069.	0.5	8
111	A short-term high fat diet increases exposure to midazolam and omeprazole in healthy subjects. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 715-720.	3.3	12
112	The Effect of Weight and CYP3A5 Genotype on the Population Pharmacokinetics of Tacrolimus in Stable Paediatric Renal Transplant Recipients. Clinical Pharmacokinetics, 2016, 55, 1129-1143.	3.5	27
113	Prevalence and Implications of Abnormal Laboratory Results in Patients in the Terminal Phase of Life. Journal of Palliative Medicine, 2016, 19, 822-829.	1.1	8
114	A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patients. Haematologica, 2016, 101, 1159-1169.	3.5	39
115	Pharmacodynamics and Pharmacokinetics of Morphine After Cardiac Surgery in Children With and Without Down Syndrome. Pediatric Critical Care Medicine, 2016, 17, 930-938.	0.5	26
116	Quantitative Method for Simultaneous Analysis of a 5-Probe Cocktail for Cytochrome P450 Enzymes. Therapeutic Drug Monitoring, 2016, 38, 761-768.	2.0	10
117	Altered gentamicin pharmacokinetics in term neonates undergoing controlled hypothermia. British Journal of Clinical Pharmacology, 2016, 81, 1067-1077.	2.4	36
118	Pharmacokinetics of Morphine, Morphine-3-Glucuronide and Morphine-6-Glucuronide in Terminally Ill Adult Patients. Clinical Pharmacokinetics, 2016, 55, 697-709.	3.5	23
119	Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2016, 14, 251-258.e2.	4.4	171
120	Pharmacokinetics of midazolam and its metabolites in terminally ill adult patients Journal of Clinical Oncology, 2016, 34, e21506-e21506.	1.6	0
121	Phase I study of everolimus combined with metformin for patients with advanced cancer Journal of Clinical Oncology, 2016, 34, e14088-e14088.	1.6	0
122	The "OPTI-CLOT―trial. Thrombosis and Haemostasis, 2015, 114, 639-644.	3.4	22
123	Short-Term Fasting Alters Cytochrome P450–Mediated Drug Metabolism in Humans. Drug Metabolism and Disposition, 2015, 43, 819-828.	3.3	26
124	Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncology, The, 2015, 16, 839-847.	10.7	321
125	Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis. Gastroenterology, 2015, 149, 350-355.e2.	1.3	342
126	Medication use during end-of-life care in a palliative care centre. International Journal of Clinical Pharmacy, 2015, 37, 767-775.	2.1	67

#	Article	IF	CITATIONS
127	Phase II Study on Bortezomib (BTZ) in Multiple Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (rALL): High Response Rate with a Modestly Intensive Regimen Including BTZ, Not Related to Pharmacokinetics. Blood, 2015, 126, 2501-2501.	1.4	1
128	Perioperative FVIII Concentrate Treatment in Mild Hemophilia a Patients Shows a High Rate of Overdosing - David/Opti-Clot Studies. Blood, 2015, 126, 3510-3510.	1.4	2
129	Population Pharmacokinetics of Erwinia Asparaginase in Pediatric ALL Patients. Blood, 2015, 126, 1281-1281.	1.4	2
130	Clinical Evaluation of Vancomycin Dosage in Pediatric Oncology Patients. Pediatric Infectious Disease Journal, 2014, 33, 731-733.	2.0	6
131	A simple quantitative method analysing amikacin, gentamicin, and vancomycin levels in human newborn plasma using ion-pair liquid chromatography/tandem mass spectrometry and its applicability to a clinical study. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 2014, 951-952, 110-118.	2.3	67
132	Population pharmacokinetics of paracetamol across the human ageâ€range from (pre)term neonates, infants, children to adults. Journal of Clinical Pharmacology, 2014, 54, 619-629.	2.0	42
133	Inadequate vancomycin therapy in term and preterm neonates: a retrospective analysis of trough serum concentrations in relation to minimal inhibitory concentrations. BMC Pediatrics, 2014, 14, 193.	1.7	36
134	A phase II randomized, placebo controlled study to evaluate the efficacy of the combination of gemcitabine, erlotinib, and metformin in patients with locally advanced or metastatic pancreatic cancer Journal of Clinical Oncology, 2014, 32, 4021-4021.	1.6	5
135	A novel 6-mercaptopurine oral liquid formulation for pediatric acute lymphoblastic leukemia patients $\tilde{\mathbb{A}}$ ¢ $\hat{\mathbb{A}}$ ÷ $\hat{\mathbb{A}}$ " results of a randomized clinical trial. International Journal of Clinical Pharmacology and Therapeutics, 2014, 52, 653-662.	0.6	2
136	Targeting Clotting Factor VIII Plasma Values in the Perioperative Setting in Hemophilia a: "Tackling a Moving Target―("OPTI-CLOT―Studies). Blood, 2014, 124, 5031-5031.	1.4	0
137	Effect of hypothermia and extracorporeal life support on drug disposition in neonates. Seminars in Fetal and Neonatal Medicine, 2013, 18, 23-27.	2.3	15
138	Pharmacokinetic–Pharmacodynamic Modeling of the Antihypertensive Effect of Eprosartan in Black and White Hypertensive Patients. Clinical Pharmacokinetics, 2013, 52, 793-803.	3.5	6
139	Effect of Intravenous Paracetamol on Postoperative Morphine Requirements in Neonates and Infants Undergoing Major Noncardiac Surgery. JAMA - Journal of the American Medical Association, 2013, 309, 149.	7.4	193
140	Nonlinear Mixed Effects Modeling of the Diurnal Blood Pressure Profile in a Multiracial Population. American Journal of Hypertension, 2013, 26, 1103-1113.	2.0	8
141	Pharmacokinetics and pharmacodynamics of medication in asphyxiated newborns during controlled hypothermia. The PharmaCool multicenter study. BMC Pediatrics, 2012, 12, 45.	1.7	43
142	Intraâ€patient variability in tacrolimus trough concentrations and renal function decline in pediatric renal transplant recipients. Pediatric Transplantation, 2012, 16, 613-618.	1.0	38
143	Acute liver failure after recommended doses of acetaminophen in patients with myopathies. Critical Care Medicine, 2011, 39, 678-682.	0.9	22
144	Nonlinear Relationship between Mycophenolate Mofetil Dose and Mycophenolic Acid Exposure. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 656-663.	4.5	60

#	Article	IF	Citations
145	Therapeutic Drug Monitoring for the Individualization of Docetaxel Dosing: A Randomized Pharmacokinetic Study. Clinical Cancer Research, 2011, 17, 353-362.	7.0	59
146	Ultrafast selective quantification of methotrexate in human plasma by high-throughput MALDI-isotope dilution mass spectrometry. Bioanalysis, 2011, 3, 1369-1378.	1.5	18
147	Sample Collection, Biobanking, and Analysis. Handbook of Experimental Pharmacology, 2011, 205, 203-217.	1.8	4
148	Simultaneous assay of sildenafil and desmethylsildenafil in neonatal plasma by ultraâ€performance liquid chromatography–tandem mass spectrometry. Biomedical Chromatography, 2010, 24, 180-185.	1.7	17
149	Differences in Clearance of Mycophenolic Acid Among Renal Transplant Recipients, Hematopoietic Stem Cell Transplant Recipients, and Patients With Autoimmune Disease. Therapeutic Drug Monitoring, 2010, 32, 606-614.	2.0	34
150	Methotrexate-induced side effects are not due to differences in pharmacokinetics in children with Down syndrome and acute lymphoblastic leukemia. Haematologica, 2010, 95, 1106-1113.	3.5	71
151	Quantification of midazolam, morphine and metabolites in plasma using 96â€well solidâ€phase extraction and ultraâ€performance liquid chromatography–tandem mass spectrometry. Biomedical Chromatography, 2010, 24, 969-976.	1.7	20
152	Quantification of levetiracetam in plasma of neonates by ultra performance liquid chromatography–tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2010, 878, 675-681.	2.3	33
153	High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation. Nephrology Dialysis Transplantation, 2010, 25, 2757-2763.	0.7	210
154	Pharmacokinetics of Cefotaxime and Desacetylcefotaxime in Infants during Extracorporeal Membrane Oxygenation. Antimicrobial Agents and Chemotherapy, 2010, 54, 1734-1741.	3.2	56
155	Enhanced Paracetamol Clearance with Molecular Adsorbents Recirculating System (MARS \hat{A}^{\otimes}) in Severe Autointoxication. Blood Purification, 2010, 30, 118-119.	1.8	11
156	Population Pharmacokinetics of Midazolam and Its Metabolites during Venoarterial Extracorporeal Membrane Oxygenation in Neonates. Clinical Pharmacokinetics, 2010, 49, 407-419.	3.5	69
157	Sildenafil exposure in neonates with pulmonary hypertension after administration via a nasogastric tube. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2010, 95, F109-F114.	2.8	52
158	Combination Therapy of Advanced Invasive Pulmonary Aspergillosis in Transiently Neutropenic Rats Using Human Pharmacokinetic Equivalent Doses of Voriconazole and Anidulafungin. Antimicrobial Agents and Chemotherapy, 2009, 53, 2005-2013.	3.2	41
159	Microanalysis of \hat{l}^2 -Lactam Antibiotics and Vancomycin in Plasma for Pharmacokinetic Studies in Neonates. Antimicrobial Agents and Chemotherapy, 2009, 53, 75-80.	3.2	52
160	Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients. Journal of Pharmacokinetics and Pharmacodynamics, 2009, 36, 541-564.	1.8	73
161	Pharmacokinetic Modelling of the Plasma Protein Binding of Mycophenolic Acid in Renal Transplant Recipients. Clinical Pharmacokinetics, 2009, 48, 463-476.	3.5	35
162	Limited Sampling Strategies for Therapeutic Drug Monitoring of Mycophenolate Mofetil Therapy in Patients With Autoimmune Disease. Therapeutic Drug Monitoring, 2009, 31, 382-390.	2.0	31

#	Article	IF	CITATIONS
163	Inosine Monophosphate Dehydrogenase Messenger RNA Expression Is Correlated to Clinical Outcomes in Mycophenolate Mofetil-Treated Kidney Transplant Patients, Whereas Inosine Monophosphate Dehydrogenase Activity Is Not. Therapeutic Drug Monitoring, 2009, 31, 549-556.	2.0	23
164	Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T>C polymorphism. Pharmacogenetics and Genomics, 2009, 19, 626-634.	1.5	71
165	Improved Assay for the Nonradioactive Determination of Inosine 5'-Monophosphate Dehydrogenase Activity in Peripheral Blood Mononuclear Cells. Therapeutic Drug Monitoring, 2009, 31, 351-359.	2.0	51
166	Limited Sampling Strategies Drawn Within 3 Hours Postdose Poorly Predict Mycophenolic Acid Area-Under-the-Curve After Enteric-Coated Mycophenolate Sodium. Therapeutic Drug Monitoring, 2009, 31, 585-591.	2.0	27
167	Pharmacokinetics and analgesic effects of intravenous propacetamol vs rectal paracetamol in children after major craniofacial surgery. Paediatric Anaesthesia, 2008, 18, 582-592.	1.1	52
168	Effect of <i>CYP2C19</i> *2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians. British Journal of Clinical Pharmacology, 2008, 65, 752-760.	2.4	72
169	Population Pharmacokinetics of Mycophenolic Acid. Clinical Pharmacokinetics, 2008, 47, 827-838.	3.5	79
170	Caspofungin Prolongs Survival of Transiently Neutropenic Rats with Advanced-Stage Invasive Pulmonary Aspergillosis. Antimicrobial Agents and Chemotherapy, 2008, 52, 1345-1350.	3.2	15
171	Pharmacokinetics of Aztreonam in Healthy Subjects and Patients with Cystic Fibrosis and Evaluation of Dose-Exposure Relationships Using Monte Carlo Simulation. Antimicrobial Agents and Chemotherapy, 2007, 51, 3049-3055.	3.2	50
172	Irinotecan chemotherapy during valproic acid treatment: Pharmacokinetic interaction and hepatotoxicity. Cancer Biology and Therapy, 2007, 6, 1364-1370.	3.4	22
173	Therapeutic drug monitoring of mycophenolic acid: does it improve patient outcome?. Expert Opinion on Drug Metabolism and Toxicology, 2007, 3, 251-261.	3.3	32
174	Time-Dependent Clearance Decrements of Fluvoxamine in Depressed Inpatients. Journal of Clinical Psychopharmacology, 2007, 27, 231-233.	1.4	1
175	Alternative drug formulations of docetaxel: a review. Anti-Cancer Drugs, 2007, 18, 95-103.	1.4	181
176	Pharmacokinetics of Mycophenolate Mofetil in Hematopoietic Stem Cell Transplant Recipients. Therapeutic Drug Monitoring, 2007, 29, 353-360.	2.0	39
177	Medicinal Cannabis Does Not Influence the Clinical Pharmacokinetics of Irinotecan and Docetaxel. Oncologist, 2007, 12, 291-300.	3.7	62
178	Time-dependent clearance of mycophenolic acid in renal transplant recipients. British Journal of Clinical Pharmacology, 2007, 63, 741-752.	2.4	63
179	Influence of ketoconazole on the fecal and urinary disposition of docetaxel. Cancer Chemotherapy and Pharmacology, 2007, 60, 569-579.	2.3	13
180	Individualisation of mycophenolate mofetil dose in renal transplant recipients. Expert Opinion on Pharmacotherapy, 2006, 7, 361-376.	1.8	19

#	Article	IF	CITATIONS
181	Within-Patient Variability of Mycophenolic Acid Exposure. Therapeutic Drug Monitoring, 2006, 28, 31-34.	2.0	28
182	Pharmacokinetics and Pharmacodynamics of Midazolam and Metabolites in Nonventilated Infants after Craniofacial Surgery. Anesthesiology, 2006, 105, 1135-1146.	2.5	52
183	Population Pharmacokinetics and Pharmacodynamics of Nelfinavir and Its Active Metabolite M8 in HIV-1-Infected Children. Pediatric Infectious Disease Journal, 2006, 25, 538-543.	2.0	12
184	Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel. Cancer Biology and Therapy, 2006, 5, 833-839.	3.4	38
185	Explaining Variability in Mycophenolic Acid Exposure to Optimize Mycophenolate Mofetil Dosing. Journal of the American Society of Nephrology: JASN, 2006, 17, 871-880.	6.1	175
186	Caspofungin: antifungal activity in vitro, pharmacokinetics, and effects on fungal load and animal survival in neutropenic rats with invasive pulmonary aspergillosis. Journal of Antimicrobial Chemotherapy, 2006, 57, 732-740.	3.0	46
187	Predicting the Usefulness of Therapeutic Drug Monitoring of Mycophenolic Acid. Therapeutic Drug Monitoring, 2005, 27, 163-167.	2.0	32
188	Cyclosporine Interacts with Mycophenolic Acid by Inhibiting the Multidrug Resistance-Associated Protein 2. American Journal of Transplantation, 2005, 5, 987-994.	4.7	278
189	Estimation of the glomerular filtration rate in children: which algorithm should be used?. Pediatric Nephrology, 2005, 20, 1769-1775.	1.7	30
190	Peginterferon and Dose-Titrated Ribavirin for Hepatitis C-Associated Nephrotic Membranoproliferative Glomerulonephritis Type 1. Digestive Diseases and Sciences, 2005, 50, 1804-1806.	2.3	6
191	Population Pharmacokinetics of Mycophenolic Acid in Renal Transplant Recipients. Clinical Pharmacokinetics, 2005, 44, 1083-1096.	3.5	85
192	Bayesian Pharmacokinetically Guided Dosing of Paclitaxel in Patients with Non-Small Cell Lung Cancer. Clinical Cancer Research, 2004, 10, 2237-2244.	7.0	47
193	Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the and genes. Clinical Pharmacology and Therapeutics, 2004, 76, 545-556.	4.7	153
194	Mycophenolic Acid in Diabetic Renal Transplant Recipients. Therapeutic Drug Monitoring, 2004, 26, 620-625.	2.0	40
195	Optimal Sampling Strategies to Assess Inulin Clearance in Children by the Inulin Single-Injection Method. Clinical Chemistry, 2003, 49, 1170-1179.	3.2	25
196	Impact of Goal-Oriented and Model-Based Clinical Pharmacokinetic Dosing of Aminoglycosides on Clinical Outcome: A Cost-Effectiveness Analysis. Therapeutic Drug Monitoring, 1999, 21, 63-73.	2.0	214